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ABSTRACT
Purpose of review:
Vancomycin is a first-line agent in the treatment of serious Gram-positive infections
in the neonatal population. The published evidence on vancomycin toxicity in
neonates is limited. This review summarises pre-clinical studies and clinical trials
describing vancomycin toxicity. We discuss proposed pathophysiology and
summarise evidence supporting dose-response relationships, genetic and
environmental determinants, and consider future research required to further define
vancomycin toxicity.
Recent findings:
Current dosing regimens for vancomycin result in sub-therapeutic levels in a large
proportion of patients. Higher daily doses have been proposed, which have led to
concerns regarding increased toxicity. Nephrotoxicity occurs in 1-9% of neonates
receiving currently recommended doses. The incidence is highest in those receiving
concomitant nephrotoxic drugs. Vancomycin-associated ototoxicity is rare in patients
of all ages. Exposure-toxicity relationships in relation to nephro- and ototoxicity have
not been clearly defined in neonates receiving vancomycin.
Summary:
Current evidence supports the favourable safety profile of vancomycin in neonates.
Further studies that address safety concerns relating to high-dose intermittent dosing
regimens are needed. Such studies must include robust and standardised definitions of
renal and hearing impairment, and include follow-up of sufficient length to establish
the long-term implications of experimental findings.
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INTRODUCTION
Vancomycin is a glycopeptide bactericidal antibiotic that disrupts cell wall synthesis
in Gram-positive bacteria. (1) Impurities from early fermentation processes were
associated with significant toxicity when the drug was first introduced in the early
the disparaging
the safety profile of vancomycin, and Food and Drug Administration approval was
granted in 1958. Despite this,
use. In recent decades clinical use has increased, however, owing to the rising
incidence of infections caused by methicillin-resistant Staphylococcus aureus and
other resistant Gram-positive pathogens that are susceptible to vancomycin. (2)
Vancomycin dosing strategies vary greatly and are generally based on a combination
of post-menstrual age (PMA), post-natal age (PNA), weight and/or renal function (see
table 1). Therapeutic drug monitoring (TDM) is widely advocated. Currently clinical
guidelines recommend target trough concentrations of 10-15 (3, 4) However,
recent studies suggest the need for target trough levels >15 , based on the
concern that lower trough concentrations may be selective for hetero-resistance. (5-7)
In adults, higher daily doses of vancomycin (15 mg/kg 6 hourly) have yet to receive
regulatory approval but have been proposed in recent consensus documents published
by the Infectious Diseases Society of America, American Society of Health-System
Pharmacists, and the Society of Infectious Diseases Pharmacists. (8-10) The use of
higher vancomycin doses has raised concerns regarding the potentially increased risk
of toxicity. The significance of these concerns in paediatric populations is unclear.
Here we summarise the current evidence relating to vancomycin toxicity including
proposed pathophysiology, dose-toxicity relationships, genetic and environmental
factors and future research needs. Studies pertaining to vancomycin-induced toxicity
between March 1950 and March 2015 were identified from PubMed, Embase,
Cochrane Controlled Trial Registry, and Medline databases. The following search
NEPHROTOXICITY
Quantification of Nephrotoxicity
Kidney function is difficult to define in the first month of life when renal physiology
and fluid balance evolve rapidly. Serum creatinine (SCr) concentrations reflect
maternal renal function in the first 48 hours after birth. (11, 12) In addition, preterm
infants experience a rise in SCr due to tubular reabsorption, making this an imprecise
proxy for glomerular filtration. (13) Clinical reports also often omit details of the
laboratory methods used to quantify SCr (Jaffé colorimetry, enzymatic quantification,
or isotope dilution mass spectroscopy), which can have an inter-test variability of up
to 25% in neonates. (14, 15) Despite these limitations most studies define renal
impairment as an increase in SCr. (16-19) Definitions for children and neonates have
been reported based on several classifications systems, all of which were originally
developed and validated in adults. (20, 21) Modified neonatal criteria exclude urine
output or use a higher cut-off (< 1.0 mL/kg/h) in order to account for the non-oliguric
renal dysfunction that occurs in neonates due to fluid redistribution and impaired
absorption in the immature renal tubule. (22, 23)
Pre-Clinical Studies
Murine models have demonstrated that vancomycin has an affinity for biological
membranes and accumulates in renal tissue. (24, 25) The energy-dependent transport
mechanisms within the tubular epithelium render the kidney highly susceptible to
toxin-induced cellular injury. Vancomycin enhances cellular ATP concentrations and
stimulate oxygen consumption, resulting in oxidative phosphorylation. (26-31)
However, oxidative stress of sufficient magnitude to cause clinically detectable renal
impairment has not been demonstrated in animals, even at supra-therapeutic doses.
(32) Histopathological changes and biochemical evidence of nephrotoxicity have been
observed in an uninfected murine model in which high-dose vancomycin was co-
administered with tobramycin. (25)
Clinical Studies
The linear relationship between SCr and vancomycin exposure reflects the drugs
primary route of elimination through renal excretion. As a result, a decrease in renal
function from any cause will increase serum vancomycin concentrations, a fact that
confounds the establishment of exposure-toxicity relationships. (33) Many studies
that describe vancomycin-associated nephrotoxicity are conducted in patients
otherwise at risk of renal impairment, such as those requiring intensive care and
frequently include those receiving other potentially nephrotoxic drugs (e.g. NSAIDs,
diuretics and aminoglycoside antibiotics) . However, irrespective of the difficulty in
defining causal relationships, acute kidney injury from any cause is associated with a
significantly increased risk of mortality, hospital length of stay, and cost, even after
adjustment for age, gender, chronic kidney disease, and co-morbidities at admission.
(34)
Adult Studies
Nephrotoxicity in patients receiving vancomycin has been more systematically
reported in adults than in neonates and children. The reported incidence of
nephrotoxicity in adults receiving vancomycin is 10-15%. (35) In a recent meta-
analysis, van Hal, et al. reviewed fifteen studies in which vancomycin was
administered via intermittent infusion to adults >18 years of age. Randomised trials
and observational studies in which data on renal function and trough vancomycin
concentrations were available were included. The analysis found trough
nephrotoxicity (OR, 2.67; 95% CI, 1.95-3.65), and also suggested an incremental
increase in nephrotoxicity risk with vancomycin administration beyond seven days.
(36) The majority of reported cases were self resolving, with prolonged impairment
requiring short-term dialysis occuring in 3% of cases. Similarly, a retrospective cohort
study of 246 adults receiving intermittent-dosing of vancomycin for durations of >48
hours found toxicity to be correlated with exposure (based on dose). Patients
compared with those receiving <4 g daily (34.6% vs. 10.9%; p = 0.001). (18)
Concomitant aminoglycoside use has consistently been shown to increase the risk of
nephrotoxicity in adults receiving vancomycin. In 2007, Fowler, et al reported a
seminal open-label randomised trial of daptomycin versus either anti-staphylococcal
penicillin or vancomycin plus low-dose gentamicin in 236 patients with S. aureus
bacteremia. The highest proportion of renal impairment occurred in patients receiving
vancomycin plus gentamicin (20.4%), although this was not significantly higher than
with penicillin plus gentamicin (18.6%).
Furthermore, the study found that the highest incidence of renal impairment in
patients receiving vancomycin occurred later in treatment, peaking at 14-28 days. (37)
Paediatric & Neonatal Studies
Vancomycin administration with intermittent dosing and in accordance with
published guidance has been shown to result in sub-therapeutic trough concentrations
in up to half of treated neonates. (4) Furthermore, antimicrobial point prevalence
surveys that describe prescribing practices have demonstrated that significant
variation in prescribing of vancomycin in neonates exists in clinical practice, with a
large proportion of neonates receiving daily doses of vancomycin that are
significantly below even the most conservative current recommendations. (38) Table
2 outlines the clinical studies that have reported nephrotoxicity associated with
vancomycin use in neonates and infants. The majority of studies identified are
heterogeneous observational or opportunistic pharmacokinetic studies based on
routine TDM and are insufficiently powered to detect toxicity.
As with adults, cases of renal impairment are more frequently reported in neonates
and children receiving concomitant nephrotoxic drugs. (19, 35) Eight of ten studies
describing concomitant nephrotoxic drugs alongside vancomycin therapy
demonstrated evidence of renal impairment, which was mild and transient in all
reported cases (see table 2). Other reports have not found vancomycin to be an
independent predictor of nephrotoxicity. Constance, et al, for example, found no
significant difference in the proportion of neonates developing nephrotoxicity in those
receiving vancomycin plus gentamicin (12/533, 2.2%) versus those receiving
gentamicin alone (7/533, 1.3%). Logistic regression demonstrated that while positive
blood culture, low birth weight, patent ductus arteriosus, concomitant non-steroidal
anti-inflammatory drug (NSAID) use, and illness severity were all independent risk
factors for nephrotoxicity, vancomycin in conjunction with gentamicin was not. (23)
Six studies report rates of nephrotoxicity in neonates receiving vancomycin alone. A
transient rise in SCr, microproteinuria, and elevated NAG were reported in only three,
two and one patient, respectively (see table 2). (51, 54, 59-61)
Exposure-toxicity relationships have not been clearly defined for vancomycin in
neonates. Two case reports have described clinical outcomes in four neonates
receiving accidental overdoses of up to 10-fold the maximum recommended dose.
(51, 59) All four patients developed transient renal impairment, though all had normal
renal function at 6 months. It is noteworthy that these cases all involved single or
brief exposures that were managed with immediate vancomycin withdrawal, and so
these findings do not address the potential risk of cumulative exposure.
A number of recent studies have described the administration of vancomycin via
continuous infusion in neonates. Continuous infusion has the theoretical advantage of
maintaining constant plasma concentrations, meaning that overall drug exposure can
be increased without a rise in peak concentrations. Studies investigating continuous
vancomycin infusions in neonates have, to date, been based on studies defined
toxicity differently and involved small patient cohorts that received varied dosing
regimens. A loading dose of 7-15 mg/kg was given in three studies. Collectively, the
results of these studies suggest that continuous infusion may result in a higher
proportion of patients achieving target concentrations between 15-
Reported rates of nephrotoxicity do not differ significantly from those in patients
receiving intermittent dosing, and there is currently no evidence to suggest the use of
a loading dose increases the risk of nephrotoxicity. (3, 45, 47, 60) Continuous
infusions may, however, be impractical in the neonatal population where venous
access if limited, and may lead to periods without effective antibiotic cover if access
is lost. There have, as yet, been no systematic studies comparing the safety and
efficacy of continuous infusion with high-dose intermittent regimens that specifically
OTOTOXICITY
Quantification of Ototoxicity in Neonates
The assessment of hearing in infants is challenging. Behavioural tests (e.g. visual
reinforcement audiometry) are the gold standard, but cannot be performed reliably in
children below ~8 months. (67) The methods currently employed to quantify auditory
function in neonates are otoacoustic emissions (OAE) and auditory brainstem
responses (ABR). Serial diagnostic OAE and ABR testing has been used to monitor
ototoxicity in children receiving aminoglycosides. (68-71) There are no equivalent
reports describing serial OAE or ABR following vancomycin use. Diagnostic OAE or
ABR is labour-intensive and difficult to interpret in premature infants (PMA <34
weeks) due to immaturity of the cochlea and central auditory pathways (72-78).
Universal newborn hearing screening (UNHS) uses a combination of automated OAE
and ABR, and is designed to identify severe permanent hearing impairment in term
neonates. Standardised UNHS programmes are now being implemented in the USA
and Europe. (79, 80) UNHS is a single-point assessment and is not designed to detect
and monitor subtle high-frequency hearing loss that typically occurs in drug-induced
ototoxicity.
Pre-Clinical Studies
The association between vancomycin use and hearing impairment is controversial. As
in the case of nephrotoxicity, the mechanism of vancomycin-induced ototoxicity is
thought to involve dose-dependent intracellular oxidative damage, which leads to the
loss of cochlear sensory hair cells resulting in high frequency hearing loss. (81)
Ototoxicity has not been consistently demonstrated with vancomycin in animal
models. (25, 82-84) Studies in guinea pigs found no evidence of vancomycin
ototoxicity, but found that vancomycin increases the probability of ototoxicity,
measured by OAE, when co-administered with gentamicin. (85)
Clinical Studies
The majority of vancomycin-
use in patients treated with indeterminate doses of an impure fermentation product
who often received concomitant therapy with other severely ototoxic agents. (86, 87)
Overall, the available recent literature on vancomycin-associated ototoxicity are
heterogeneous and in many cases causation is uncertain.
Adult Studies
Observational studies have suggested the risk of ototoxicity may be increased with
vancomycin doses in adults. In a retrospective study of 89 adults receiving
> 14 days of high-dose vancomycin, Forouzesh, et al reported high-frequency hearing
loss identified by pure-tone audiometry in ten patients (12%), a rate significantly
higher than reported at standard doses. (88) However, the study included patients
receiving concomitant aminoglycosides and diuretics, and idenfitied no significant
difference in mean trough vancomycin concentrations in patients with and without
abnormal audiometry, suggesting the phenomenon was unlikely to be dose dependent.
Paediatric & Neonatal Studies
Ototoxicity is infrequently reported in neonates and children treated with vancomycin
in general. (89) Buckingham, et al, however, reported a high incidence of hearing loss
in children with pneumococcal meningitis treated with vancomycin. (90) Patients
aged 5-20 years (n=109) received vancomycin alongside a third-generation
cephalosporin. Over half of those surviving had significant permanent hearing loss
(n=37, 55%). Of note, hearing loss was independently associated with vancomycin
administration within two hours of presentation. Whether these findings apply to
other populations or reflect the specific pathophysiology of pneumococcal meningitis
is uncertain. The findings do, however, highlight the need to consider population and
disease-specific factors when reporting drug toxicity.
In neonates, reporting of vancomycin-associated ototoxicity comes almost exclusively
from routine UNHS. De Hoog, et al studied 625 neonates over two years from a
single NICU in the Netherlands. Exposure to vancomycin (alone or in combination
with tobramycin or furosemide) was not associated with a significant rise in screening
failure rates. (91) Similarly, in a retrospective study of >7000 infants, Gopel, et al
found no association between vancomycin exposure and UNHS failure rates. (92)
Vella-Brincat, et al described UNHS outcomes over five years from a single centre in
New Zealand. The cohort included 41 neonates who received vancomycin, and found
higher failure rates (n=6; 22%), compared with those not exposed to vancomycin (n =
85/1,233; 7%). The significance of these finding is uncertain given the lack of
systematic follow-up and many potential confounding factors.
CONCLUSION
Despite historical concerns, a large body of evidence now exists to support the
favourable safety profile of vancomycin in humans. In adults, nephrotoxicity is
exposure-dependent, and more aggressive dosing may result in a significantly
increased risk of toxicity. By comparison, current dosing regimens in neonates are
conservative, and result in sub-therapeutic concentrations in a large proportion of
patients. At present, insufficient evidence exists to inform conclusions about the
safety of higher doses of vancomycin in neonates. Furthermore, the clinical difficulty
in ascertaining a diagnosis of sepsis with certainty in neonates makes risk-benefit
analyses challenging. The development and use of novel diagnostic biomarkers are
likely to improve clinical decision-making and trial design in the years to come. (93)
Dose modification based on trough vancomycin concentrations, which are, in turn,
largely determined by renal function, adds complexity in determining exposure-
toxicity relationships. These issues are probably best addressed with detailed
prospective, observational data that define renal impairment according to standardised
criteria and allow for a more clinically valid estimation of risk.
Ototoxicity appears rare in patients of all ages treated with vancomycin. Diagnostic
OAE and ABR may detect subtle high-frequency hearing loss following vancomycin
exposure. These tests can only reliably be carried out in babies >34 weeks before
which many preterm neonates will already have receive courses of vancomycin.
UNHS at term is unlikely to detect subtle hearing impairment and identify exposure-
toxicity relationships. Prospective studies that use robust and standardised definitions
of hearing impairment based on diagnostic testing, such as with visual reinforcement
audiometry at 8-12 months, are needed to further clarify the risk clinically significant
ototoxicity.
Source PMA (weeks) PNA (days) Creatinine (mg/dL) Dose (mg/kg) Interval (hourly)
British National Formulary for Children
Manual of Childhood Infections: The Blue Book
<29 15 24
29 35 15 12
>35 15 8
Neofax®
The Harriet Lane Handbook
The Sanford guide
0 14 10 (bactaeremia)
15 (meningitis)
18
>14 10 12
30 36 0 14 10 12
>14 10 8
37 44 0 7 10 12
>7 10 8
Any PNA 10 6
<0.7 15 12
Table 1. Current dosing regimens for vancomycin in neonates
Red Book® 2015 Report of the Committee on
Infectious Disease
0.7 0.9 20 24
1 1.2 15 24
1.3 1.6 10 24
>1.6 15 48
Table 2. Studies describing nephrotoxicity in neonates receiving vancomycin
Author (year)
Design
Study population receiving
vancomycin
(mean ± SD unless
otherwise stated)
Dosing regimen Concomitant
nephrotoxic
agents
Timing/Target Nephrotoxicity
Definition
Incidence of
nephrotoxicity
Constance (2015)
Propensity-
matched cohort
study (23)
n = 533
PMA <25 weeks n = 35, 25-
28 weeks n = 73, 28-32
weeks n = 158, 32-27 weeks
n = 152, >37 weeks n = 115
weight 1649 (1060-2504) g
median (IQR)
Intermittent infusion: 12-40
mg/kg per day (not further
described)
Gentamicin
Ibuprofen
Timing and
target
concentrations
not reported
SCr rise by
hours or SCr
mg/dL (132
µmol/L)
h
Transient rise in SCr in
12/533 patients receiving
vancomycin with
gentamicin
Moffett (2015)
Retrospective
case-control
study (39)
n= 83 neonates with critical
cardiac disease
Not specified Gentamicin
Furosemide
Amphotericin
Doubling of SCr 2 developed AKI. AKI
more likely with
concomitant nephrotoxic
agents
Petrie
(2015)
Retrospective
observational
study (40)
n = 83
PMA 30+3 (23+6-52+4)
weeks, weight 1.12 (0.56-
4.7) g median (IQR)
Intermittent infusion:
15 mg/kg per dose 8-24
hourly according to PMA
Not reported Timing not
reported;
trough 10 15
Rise in SCr not
further defined
None detected
Vandendriessche
(2014)
Retrospective
observational
study (41)
n = 223
PMA 32 (24 41) weeks,
median (range)
1650 (420 4680) g
Intermittent infusion:
10-15 mg/kg 6-24 hourly
according to PMA, PNA
and SCr
Not reported Timing not
reported;
trough > 10
Difference in
mean SCr
None detected
Frymoyer
(2014)Prospectiv
e observational
study (42)
n = 249
PMA 39 (32 42) weeks,
weight 2900 (1600-3700) g
median (IQR)
15-20 mg/kg per dose 12-24
hourly according to SCr and
weight
Not reported After 3rd dose;
trough 7-10
Rise in SCr not
further defined
None detected
Kim (2014)
Retrospective
observational
study (43)
n=50
PMA 27.4 ± 2.5 weeks,
weight 1020 ± 420 g
15-40 mg/kg per dose 6 12
hourly according to PMA
Not reported Timing not
reported;
SCr >25% above
baseline or urine
output <1 ml/kg/h
None detected
Linder
(2013)
Retrospective
observational
study (44)
n = 126
PMA 27.5 ± 2.6 weeks,
weight 1026 ± 269 g
Intermittent infusion: 10
mg/kg per dose
8-18 hourly according to
PMA and PNA
Not reported 1-2 days;
Trough 10,
peak 30-40
Not formally
defined
None detected
Patel
(2013)
Retrospective
observational
study (3)
n = 32 (40 treatment
courses)
PMA 36 (26 62) weeks,
weight 2200 (620-6900) g
median (IQR)
n = 20
Intermittent infusion: 10-20
mg/kg per dose 8-12 hourly
according to SCr
n = 20
Not reported Before 3rd
dose;
15-25
Rise in mean ±
SD in SCr not
further defined
No significant rise in SCr
(mean ± SD) in either
intermittent dosing or
continuous infusion.
Continuous infusion: 20 60
mg/kg daily according to
PMA and SCr
Two patients developed
renal failure 2nd to a
decline in overall clinical
status.
Zhao
(2013)
Prospective
observational
study (45)
n = 116
PMA 33.8 ± 5.3 weeks,
weight 1700 ± 964 g
Loading dose: 10-15 mg/kg
Continuous infusion:
15-35 mg/kg daily
according to PMA, PNA
and SCr
Not reported Timing not
reported; 15-
25
SCr > 70 or 90
µmol/L based on
PNA
None detected
Irikura
(2011)
n = 54
n = 21 (SCr-based dosing)
PMA 29.65 ± 5.27 weeks
Birthweight 1322 ± 951 g
n = 21
Intermittent infusion: 10-20
mg/kg per dose 12-48
hourly according to SCr
Not reported Timing and
target
concentrations
not reported
Rise in SCr not
further defined
Transient rise in SCr in 3
patients (two receiving
dose based on
weight/PNA and one
Prospective
observational
study
(46)
n = 33 (dosing based on
weight & PNA)
PMA 33.18 ± 5.94 weeks
Birthweight 1839 ± 915 g
n = 33
Intermittent infusion: 10
mg/kg per dose 6-18 hourly
according to weight and
PNA
receiving dosing based
on baseline SCr,
respectively).
Oudin
(2011)
PK study (47)
n = 47
PMA 29.5 ± 27, weight
1500 ± 970 g
Loading dose: 7 mg/kg
Continuous infusion:
30mg/kg daily
Not reported Timing not
reported;
trough 10-30
Rise in SCr not
further defined
Transient rise in SCr in 3
patients resolved by 3
weeks after exposure.
Plan
(2008)
Prospective
observational
study (48)
n = 145
PMA 28 (26 29) weeks,
Weight 904 (780 1160) g
median (IQR)
Intermittent infusion:
15-30 mg/kg per dose 24
hourly according to SCr
Diuretics, not
further defined
Timing not
reported;
trough 10-25
Rise in SCr not
further defined
No significant rise in SCr
detected
Giapros
(2007)
Retrospective
observational
study (49)
n = 70
Weight <1000 g
Intermittent infusion every
12 48 h not further
defined
Gentamicin Timing and
target not
reported
Increased urinary
excretion of
potassium,
calcium and
phosphate; raised
SCr
5 patients with severe
renal tubular disturbance
(3 with raised SCr). All
abnormalities returned to
baseline within 2 weeks
of the last antibiotic
course
Frattarelli
(2005)
Retrospective
observational
study (50)
n = 153
SGA; PMA 48 ± 8 weeks,
weight 641 ± 181 g
Non-SGA; PMA 47 ± 8
weeks, weight 1158 ± 765 g
Intermittent infusion not
further defined
Not reported Timing not
reported;
trough, target
not reported
Rise in SCr not
further defined
None detected
Miner
(2004)
n = 2 Intermittent infusion: None Timing not
reported; peak
Rise in SCr not
further defined
Transient rise SCr in one
patient
Case series (51) Case 1 PMA 24 weeks at
birth. Day 53 of life when
vancomycin commenced
Case 2 PMA 28 weeks at
birth. Vancomycin
commenced day 9 of life
150 mg/kg (10x accidental
overdose)
concentration,
>300
Deville
(2003)
Phase III, open
label RCT (52)
n = 20
PMA 38.6 ± 7.3 weeks
Population not further
defined
Intermittent infusion:
10-15 mg/kg per dose 6-24
hourly according to PMA
Gentamicin Timing not
reported;
trough, target
not reported
SCr twice the
upper limit of
normal or double
baseline
Transient rise in SCr in
one patient not further
described
Tan
(2002)
n = 101
PMA 30 (23 45) weeks
Median (range)
Intermittent infusion:
15 mg/kg per dose 12-18
hourly according to PNA
Not reported Timing not
reported;
trough < 10
Difference in
mean SCr
None detected
Retrospective
observational
study (53)
Population not further
defined
Feferbaum
(2001)
Prospective
observational
study (54)
n = 20
PMA 42 ± 3 weeks
Population not further
defined
Intermittent infusion:
30-60 mg/kg per day (not
further described)
None Timing not
reported;
trough 5-10,
peak 30-40
Rise in SCr not
further defined
None detected
Machado
(2001)
Prospective
observational
study (55)
n = 25
PMA 38 ± 1 weeks,
3130 ± 861.3 g
10-20 mg/kg per dose 6-24
hourly according to PMA
Gentamicin Timing not
reported;
trough 5-10,
peak 20-40
Rise in SCr and
urea 5 days after
treatment started
not otherwise
further defined
Significant transient rise
in intra-individual SCr
but not urea. Not further
described.
De Hoog
(2000)
Retrospective
observational
study (56)
n = 108
PMA 28.9 (24 41) weeks
Birthweight 1002 g (485
4625 g)
Median (IQR)
Intermittent infusion:
30 mg/kg per dose 12
hourly
Not reported Steady state
(not further
defined); Peak
-
15
Increase in SCr or
urea not further
defined
None detected
Bhatt-Mehta
(1999)
Retrospective
observational
study (57)
n = 69
PMA 28.9 ± 3.0 weeks,
weight 1219 ± 516 g
Intermittent infusion:
10-15 mg/kg per dose every
6-36 hourly according to
PMA
Gentamicin After 3rd dose; SCr double
baseline or >0.6
mg/dL (53
µmol/L)
Transient rise in SCr in
6/61 patients with peak
none with peak
concentrations >40
Goebel
(1999)
Case report (58)
n = 1
Term infant, PNA 6 d
Solitary dysplastic kidney
100 mg/kg Not reported 12 hours post
dose; no target
Anuria. Not
otherwise further
defined
Commenced
hemofiltration due to
persistently elevated
vancomycin level (240
function at PNA 3 weeks.
Müller
(1999)
Case series (59)
n = 2
PMA 35 weeks, weight
1985 and 2390 g
Intermittent infusion:
Single dose 35 mg/kg and
38 mg/kg (accidental
overdose)
None 9 hours post
dose; no target
reported
Reduced GFR or
microproteinuria
(urinary protein
electrophoresis)
Transient
microproteinuria in both
patients but no change in
GFR
Pawlotsky
(1998)
Non-randomised
un-blinded trial
(60)
n = 53
PMA 33.5 ± 3.7 weeks,
weight 1500 ± 300 g (n =
29)
PMA 33.9 ± 4.8 weeks,
weight 1800 ± 800 g (n =
24)
n = 29
Loading dose: 7 mg/kg
Continuous infusion:
10-40 mg/kg per over 24
hours according to PMA
and weight
n = 24
Continuous infusion:
None Post loading
Steady state
(not further
defined);
10-30
Rise in SCr and
urea not further
defined
Transient rise in SCr in
one patient with
klebsiella septicaemia
10-30 mg/kg per over 24
hours according to PMA
and weight
Sakata
(1996)
Prospective
observational
study (61)
n = 20
PMA 26.3 ± 1.4 weeks
Population not further
defined
Intermittent infusion: 9-11
mg/kg per dose 12 hourly
None Timing and
target
concentrations
not reported
Rise in SCr,
fractional
excretion of
sodium (FENa)
and NAG index
(NAG:creatinine
ratio)
Transient rise in NAG
index and FENa after
treatment in one patient
McDougal
(1995)
n = 44
PMA 29.4 ± 0.9 weeks,
weight 972 ± 178 g (n = 16)
Intermittent infusion:
15-18 mg/kg per dose 12-36
hourly according to PMA
Not reported Steady state
(not further
defined); peak
Increase in SCr or
urea not further
defined
None detected
Prospective
observational
study (62)
PMA 32.9 ± 1.8 weeks,
weight 1379 ± 382 g (n =
15)
PMA 39.2 ± 2 weeks,
weight 2616 ± 753 g (n =
13)
25-35, trough
5-10
Tissing (1993)
Case report (63)
n = 1
PMA 29.3 weeks, weight
1520 g
Intermittent infusion:
15 mg/kg per dose every 12
hours
Tobramycin Timing not
reported; no
target
(reported level
63.3)
Rise in SCr and
oliguria not
further defined
Transient rise in SCr and
persistently elevated
vancomycin level.
Resolution at 2 months
of age.
Lisby-Sutch
(1988)
Prospective
n = 13
PMA 29.8 ± 3.4 weeks,
weight 1350 ± 500 g
Intermittent infusion: Not reported Timing not
reported; peak
Increase in SCr or
urea not further
defined
None detected
PK study (64) 10 mg/kg per dose 6-12
hourly according to PMA
and weight
25 35, trough,
5 10
Nahata
(1987)
Prospective
observational
study (65)
n = 61 < 1 year
Further clinical information
not available.
Intermittent infusion:
20-60 mg/kg/day (mean 35)
Gentamicin Timing not
reported;
trough 2-18
Doubling of SCr
concentration
None detected
James
(1987)
Prospective PK
study (33)
n = 20
PMA 26.5 ± 2.6 weeks,
weight 880 ± 340 g
Intermittent infusion:
9-18 mg/kg per dose 12
hourly
Not reported Timing not
reported; peak
30, trough 6
Not formally
defined
None reported although
positive linear correlation
between vancomycin
level and SCr identified
Dean
(1985)
Retrospective
observational
study (66)
n = 28
Population not further
defined
Intermittent infusion:
11-55 mg/kg (mean 30
mg/kg) daily not further
defined
Gentamicin Timing not
reported; peak
20-40, trough
5-10
Increase in SCr
by >0.5 mg/dl (45
µmol/L)
Transient rise in SCr in
2/19 and 2/9 patients
receiving vancomycin
alone and with
gentamicin, respectively.
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Source PMA (weeks) PNA (days) Creatinine (mg/dL) Dose (mg/kg) Interval (hourly)
British National Formulary for Children
Manual of Childhood Infections: The Blue Book
<29 15 24
29 35 15 12
>35 15 8
Neofax®
The Harriet Lane Handbook
The Sanford guide
0 14 10 (bactaeremia)
15 (meningitis)
18
>14 10 12
30 36 0 14 10 12
>14 10 8
37 44 0 7 10 12
>7 10 8
Any PNA 10 6
Red Book® 2015 Report of the Committee on
Infectious Disease
<0.7 15 12
0.7 0.9 20 24
Table 1. Current dosing regimens for vancomycin in neonates
1 1.2 15 24
1.3 1.6 10 24
>1.6 15 48
Table 2. Studies describing nephrotoxicity in neonates receiving vancomycin
Author (year)
Design
Study population receiving
vancomycin
(mean ± SD unless
otherwise stated)
Dosing regimen Concomitant
nephrotoxic
agents
Timing/Target Nephrotoxicity
Definition
Incidence of
nephrotoxicity
Constance (2015)
Propensity-
matched cohort
study (23)
n = 533
PMA <25 weeks n = 35, 25-
28 weeks n = 73, 28-32
weeks n = 158, 32-27 weeks
n = 152, >37 weeks n = 115
weight 1649 (1060-2504) g
median (IQR)
Intermittent infusion: 12-40
mg/kg per day (not further
described)
Gentamicin
Ibuprofen
Timing and
target
concentrations
not reported
SCr rise by
hours or SCr
mg/dL (132
µmol/L)
h
Transient rise in SCr in
12/533 patients receiving
vancomycin with
gentamicin
Moffett (2015)
Retrospective
case-control
study (39)
n= 83 neonates with critical
cardiac disease
Not specified Gentamicin
Furosemide
Amphotericin
Doubling of SCr 2 developed AKI. AKI
more likely with
concomitant nephrotoxic
agents
Petrie
(2015)
Retrospective
observational
study (40)
n = 83
PMA 30+3 (23+6-52+4)
weeks, weight 1.12 (0.56-
4.7) g median (IQR)
Intermittent infusion:
15 mg/kg per dose 8-24
hourly according to PMA
Not reported Timing not
reported;
trough 10 15
Rise in SCr not
further defined
None detected
Vandendriessche
(2014)
Retrospective
observational
study (41)
n = 223
PMA 32 (24 41) weeks,
median (range)
1650 (420 4680) g
Intermittent infusion:
10-15 mg/kg 6-24 hourly
according to PMA, PNA
and SCr
Not reported Timing not
reported;
trough > 10
Difference in
mean SCr
None detected
Frymoyer
(2014)Prospectiv
e observational
study (42)
n = 249
PMA 39 (32 42) weeks,
weight 2900 (1600-3700) g
median (IQR)
15-20 mg/kg per dose 12-24
hourly according to SCr and
weight
Not reported After 3rd dose;
trough 7-10
Rise in SCr not
further defined
None detected
Kim (2014)
Retrospective
observational
study (43)
n=50
PMA 27.4 ± 2.5 weeks,
weight 1020 ± 420 g
15-40 mg/kg per dose 6 12
hourly according to PMA
Not reported Timing not
reported;
SCr >25% above
baseline or urine
output <1 ml/kg/h
None detected
Linder
(2013)
Retrospective
observational
study (44)
n = 126
PMA 27.5 ± 2.6 weeks,
weight 1026 ± 269 g
Intermittent infusion: 10
mg/kg per dose
8-18 hourly according to
PMA and PNA
Not reported 1-2 days;
Trough 10,
peak 30-40
Not formally
defined
None detected
Patel
(2013)
Retrospective
observational
study (3)
n = 32 (40 treatment
courses)
PMA 36 (26 62) weeks,
weight 2200 (620-6900) g
median (IQR)
n = 20
Intermittent infusion: 10-20
mg/kg per dose 8-12 hourly
according to SCr
n = 20
Not reported Before 3rd
dose;
15-25
Rise in mean ±
SD in SCr not
further defined
No significant rise in SCr
(mean ± SD) in either
intermittent dosing or
continuous infusion.
Two patients developed
renal failure 2nd to a
Continuous infusion: 20 60
mg/kg daily according to
PMA and SCr
decline in overall clinical
status.
Zhao
(2013)
Prospective
observational
study (45)
n = 116
PMA 33.8 ± 5.3 weeks,
weight 1700 ± 964 g
Loading dose: 10-15 mg/kg
Continuous infusion:
15-35 mg/kg daily
according to PMA, PNA
and SCr
Not reported Timing not
reported; 15-
25
SCr > 70 or 90
µmol/L based on
PNA
None detected
Irikura
(2011)
Prospective
observational
study
(46)
n = 54
n = 21 (SCr-based dosing)
PMA 29.65 ± 5.27 weeks
Birthweight 1322 ± 951 g
n = 33 (dosing based on
weight & PNA)
PMA 33.18 ± 5.94 weeks
n = 21
Intermittent infusion: 10-20
mg/kg per dose 12-48
hourly according to SCr
n = 33
Intermittent infusion: 10
mg/kg per dose 6-18 hourly
Not reported Timing and
target
concentrations
not reported
Rise in SCr not
further defined
Transient rise in SCr in 3
patients (two receiving
dose based on
weight/PNA and one
receiving dosing based
on baseline SCr,
respectively).
Birthweight 1839 ± 915 g according to weight and
PNA
Oudin
(2011)
PK study (47)
n = 47
PMA 29.5 ± 27, weight
1500 ± 970 g
Loading dose: 7 mg/kg
Continuous infusion:
30mg/kg daily
Not reported Timing not
reported;
trough 10-30
Rise in SCr not
further defined
Transient rise in SCr in 3
patients resolved by 3
weeks after exposure.
Plan
(2008)
Prospective
observational
study (48)
n = 145
PMA 28 (26 29) weeks,
Weight 904 (780 1160) g
median (IQR)
Intermittent infusion:
15-30 mg/kg per dose 24
hourly according to SCr
Diuretics, not
further defined
Timing not
reported;
trough 10-25
Rise in SCr not
further defined
No significant rise in SCr
detected
Giapros
(2007)
Retrospective
observational
study (49)
n = 70
Weight <1000 g
Intermittent infusion every
12 48 h not further
defined
Gentamicin Timing and
target not
reported
Increased urinary
excretion of
potassium,
calcium and
phosphate; raised
SCr
5 patients with severe
renal tubular disturbance
(3 with raised SCr). All
abnormalities returned to
baseline within 2 weeks
of the last antibiotic
course
Frattarelli
(2005)
Retrospective
observational
study (50)
n = 153
SGA; PMA 48 ± 8 weeks,
weight 641 ± 181 g
Non-SGA; PMA 47 ± 8
weeks, weight 1158 ± 765 g
Intermittent infusion not
further defined
Not reported Timing not
reported;
trough, target
not reported
Rise in SCr not
further defined
None detected
Miner
(2004)
Case series (51)
n = 2
Case 1 PMA 24 weeks at
birth. Day 53 of life when
vancomycin commenced
Case 2 PMA 28 weeks at
birth. Vancomycin
commenced day 9 of life
Intermittent infusion:
150 mg/kg (10x accidental
overdose)
None Timing not
reported; peak
concentration,
>300
Rise in SCr not
further defined
Transient rise SCr in one
patient
Deville
(2003)
Phase III, open
label RCT (52)
n = 20
PMA 38.6 ± 7.3 weeks
Population not further
defined
Intermittent infusion:
10-15 mg/kg per dose 6-24
hourly according to PMA
Gentamicin Timing not
reported;
trough, target
not reported
SCr twice the
upper limit of
normal or double
baseline
Transient rise in SCr in
one patient not further
described
Tan
(2002)
Retrospective
observational
study (53)
n = 101
PMA 30 (23 45) weeks
Median (range)
Population not further
defined
Intermittent infusion:
15 mg/kg per dose 12-18
hourly according to PNA
Not reported Timing not
reported;
trough < 10
Difference in
mean SCr
None detected
Feferbaum
(2001)
Prospective
observational
study (54)
n = 20
PMA 42 ± 3 weeks
Population not further
defined
Intermittent infusion:
30-60 mg/kg per day (not
further described)
None Timing not
reported;
trough 5-10,
peak 30-40
Rise in SCr not
further defined
None detected
Machado
(2001)
n = 25
PMA 38 ± 1 weeks,
10-20 mg/kg per dose 6-24
hourly according to PMA
Gentamicin Timing not
reported;
Rise in SCr and
urea 5 days after
Significant transient rise
in intra-individual SCr
Prospective
observational
study (55)
3130 ± 861.3 g trough 5-10,
peak 20-40
treatment started
not otherwise
further defined
but not urea. Not further
described.
De Hoog
(2000)
Retrospective
observational
study (56)
n = 108
PMA 28.9 (24 41) weeks
Birthweight 1002 g (485
4625 g)
Median (IQR)
Intermittent infusion:
30 mg/kg per dose 12
hourly
Not reported Steady state
(not further
defined); Peak
-
15
Increase in SCr or
urea not further
defined
None detected
Bhatt-Mehta
(1999)
Retrospective
observational
study (57)
n = 69
PMA 28.9 ± 3.0 weeks,
weight 1219 ± 516 g
Intermittent infusion:
10-15 mg/kg per dose every
6-36 hourly according to
PMA
Gentamicin After 3rd dose; SCr double
baseline or >0.6
mg/dL (53
µmol/L)
Transient rise in SCr in
6/61 patients with peak
none with peak
concentrations >40
Goebel
(1999)
Case report (58)
n = 1
Term infant, PNA 6 d
Solitary dysplastic kidney
100 mg/kg Not reported 12 hours post
dose; no target
Anuria. Not
otherwise further
defined
Commenced
hemofiltration due to
persistently elevated
vancomycin level (240
function at PNA 3 weeks.
Müller
(1999)
Case series (59)
n = 2
PMA 35 weeks, weight
1985 and 2390 g
Intermittent infusion:
Single dose 35 mg/kg and
38 mg/kg (accidental
overdose)
None 9 hours post
dose; no target
reported
Reduced GFR or
microproteinuria
(urinary protein
electrophoresis)
Transient
microproteinuria in both
patients but no change in
GFR
Pawlotsky
(1998)
Non-randomised
un-blinded trial
(60)
n = 53
PMA 33.5 ± 3.7 weeks,
weight 1500 ± 300 g (n =
29)
PMA 33.9 ± 4.8 weeks,
weight 1800 ± 800 g (n =
24)
n = 29
Loading dose: 7 mg/kg
Continuous infusion:
10-40 mg/kg per over 24
hours according to PMA
and weight
n = 24
Continuous infusion:
None Post loading
Steady state
(not further
defined);
10-30
Rise in SCr and
urea not further
defined
Transient rise in SCr in
one patient with
klebsiella septicaemia
10-30 mg/kg per over 24
hours according to PMA
and weight
Sakata
(1996)
Prospective
observational
study (61)
n = 20
PMA 26.3 ± 1.4 weeks
Population not further
defined
Intermittent infusion: 9-11
mg/kg per dose 12 hourly
None Timing and
target
concentrations
not reported
Rise in SCr,
fractional
excretion of
sodium (FENa)
and NAG index
(NAG:creatinine
ratio)
Transient rise in NAG
index and FENa after
treatment in one patient
McDougal
(1995)
Prospective
observational
study (62)
n = 44
PMA 29.4 ± 0.9 weeks,
weight 972 ± 178 g (n = 16)
PMA 32.9 ± 1.8 weeks,
weight 1379 ± 382 g (n =
15)
Intermittent infusion:
15-18 mg/kg per dose 12-36
hourly according to PMA
Not reported Steady state
(not further
defined); peak
25-35, trough
5-10
Increase in SCr or
urea not further
defined
None detected
PMA 39.2 ± 2 weeks,
weight 2616 ± 753 g (n =
13)
Tissing (1993)
Case report (63)
n = 1
PMA 29.3 weeks, weight
1520 g
Intermittent infusion:
15 mg/kg per dose every 12
hours
Tobramycin Timing not
reported; no
target (reported
level 63.3)
Rise in SCr and
oliguria not
further defined
Transient rise in SCr and
persistently elevated
vancomycin level.
Resolution at 2 months
of age.
Lisby-Sutch
(1988)
Prospective
PK study (64)
n = 13
PMA 29.8 ± 3.4 weeks,
weight 1350 ± 500 g
Intermittent infusion:
10 mg/kg per dose 6-12
hourly according to PMA
and weight
Not reported Timing not
reported; peak
25 35, trough,
5 10
Increase in SCr or
urea not further
defined
None detected
Nahata
(1987)
n = 61 < 1 year
Further clinical information
not available.
Intermittent infusion:
20-60 mg/kg/day (mean 35)
Gentamicin Timing not
reported;
trough 2-18
Doubling of SCr
concentration
None detected
Prospective
observational
study (65)
James
(1987)
Prospective PK
study (33)
n = 20
PMA 26.5 ± 2.6 weeks,
weight 880 ± 340 g
Intermittent infusion:
9-18 mg/kg per dose 12
hourly
Not reported Timing not
reported; peak
30, trough 6
Not formally
defined
None reported although
positive linear correlation
between vancomycin
level and SCr identified
Dean
(1985)
Retrospective
observational
study (66)
n = 28
Population not further
defined
Intermittent infusion:
11-55 mg/kg (mean 30
mg/kg) daily not further
defined
Gentamicin Timing not
reported; peak
20-40, trough
5-10
Increase in SCr
by >0.5 mg/dl (45
µmol/L)
Transient rise in SCr in
2/19 and 2/9 patients
receiving vancomycin
alone and with
gentamicin, respectively.
